Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Unmasking BDUC: Johanna Gebhart’s Call for Change at EHC 2025
Johanna Gebhart/LinkedIn
Oct 16, 2025, 06:03

Unmasking BDUC: Johanna Gebhart’s Call for Change at EHC 2025

 

Johanna Gebhart, Associate Professor and Haemostasis Expert at the Medical University of Vienna, shared  a post by Wolfgang Miesbach on LinkedIn:

”It was a real pleasure to present our work on Bleeding Disorder of Unknown Cause (BDUC) at EHC 2025 in Vienna.

BDUC remains a challenging and often overlooked condition – yet it affects many patients with mild to moderate bleeding where no clear cause is found. Advancing research in this field is essential to ensure these patients receive the attention and care they deserve.

Many thanks to Wolfgang Miesbach for acknowledging our work and to the European Haemophilia Consortium for providing such an inspiring platform to share and discuss these important topics.”

Quoting Wolfgang Miesbach’s post:

”Great Research at EHC 2025. The great presentation by Johanna Gebhart from the Medical University of Vienna at this year’s EHC Conference in Vienna, focused on “BDUC: a new group that deserves attention”.
Dr. Gebhart’s work on Bleeding Disorder of Unknown Cause (BDUC) may transform our understanding of this challenging diagnostic and treatment category. Her research reveals that BDUC affects up to 60% of patients with mild-to moderate bleeding disorders where no underlying cause:

– BDUC patients show bleeding phenotypes indistinguishable from other mild bleeding disorders
– Contributing factors include blood group O, increased tissue factor pathway inhibitor, activated protein C, and decreased vitamin C levels
– BDUC significantly impacts health-related quality of life despite “normal” lab results
– Treatment options remain limited with few evidence-based therapies available

As the Principal Investigator of the Vienna Bleeding Biobank (VIBB), Dr. Gebhart is pioneering research into the pathophysiology of these previously overlooked bleeding tendencies. Her work emphasizes that BDUC patients deserve the same attention and specialized care as those with well-defined bleeding disorders.”

BDUS

Stay updated with Hemostasis Today.

BDUC Bleeding Disorder Bleeding Disorder of Unknown Cause EHC EHC 2025 European Haemophilia Consortium haemophilia Health Hematology Hemostasis Hemostasis Today Johanna Gebhart Medical Research Medical University of Vienna Medicine thrombosis VIBB Vienna Bleeding Biobank Wolfgang Miesbach
NewsFeed